Description
Partnership Power at Exelixis: Leveraging Collaborations to De-Risk Clinical Expansion!
Exelixis, Inc. reported its financial results for the fourth quarter and full year 2025, illustrating significant developments and setting the stage for potential growth in 2026. The company is focused on expanding its leadership in solid tumor oncology, leveraging its established presence in GU oncology and aiming to extend this to GI indications. For the fiscal year 2025, Exelixis recorded U.S. net product revenues from its cabozantinib franchise at approximately $2.12 billion, a 17% increase from 2024, with fourth-quarter revenues reaching $547 million, marking a 6% year-over-year growth. Globally, cabozantinib franchise revenues, generated in part through partnerships with companies such as Ipsen and Takeda, totaled $2.89 billion for the year. This highlights the continued strong market performance and established position of CABOMETYX as a leading therapy in RCC and neuroendocrine tumors. The company is poised to potentially diversify its oncology portfolio with zanzalintinib.
